Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T22:16:51.571Z.
Calculation as of: 2026-10-06T22:16:51.571Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6da64a8b1a2a274dcb8686c6d20e6c80d542b1d2a14b58c5ff35188fa74041c0
PE RATIO
N/A
Market Cap
$6.60M
PE Ratio
N/A
TTM Avg
4788.36
3Y Avg
147312.95
5Y Avg
148989.26
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Femasys Inc. (FEMY) | $6.28M | N/A | N/A | N/A | N/A |
| Scienture Holdings, Inc. (SCNX)vs › | $6.11M | N/A | N/A | N/A | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.58M | N/A | 47.75 | 83.50 | 106.23 |
| Aclarion, Inc. (ACON)vs › | $6.60M | N/A | N/A | N/A | N/A |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.60M | N/A | 4788.36 | 147312.95 | 148989.26 |
| Biomerica, Inc. (BMRA)vs › | $6.61M | N/A | 278.25 | 163.06 | 336.05 |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.92M | N/A | N/A | N/A | N/A |
| Sonoma Pharmaceuticals, Inc. (SNOA)vs › | $5.89M | N/A | 5.41 | 8.45 | 9.86 |
| Lucyd, Inc (LUCY)vs › | $5.83M | N/A | N/A | N/A | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.82M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$2.08
Forward EPS (Est.)
$-2.28
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
